At EnnovaBio we are exploring multiple targeting modalities to discover novel modulators of highly validated immune checkpoint pathways. Besides immuno-oncology, we are taking similar approaches in developing innovative therapeutics for autoimmune and chronic inflammatory diseases.
A major limitation of targeted therapies is cancer cell drug resistance. Powered by human genetics, translational research and our proprietary informatics platform, we focus on targeting key signaling pathways to reduce the development of cancer cell resistance.
Contact
4F, No. 2, Lane 720, Cailun Road, Pudong New District, Shanghai, China
Tel: +86 21-50821573
ennovabio.com